Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells by Ping Li et al.
Li et al. BMC Cancer 2013, 13:297
http://www.biomedcentral.com/1471-2407/13/297RESEARCH ARTICLE Open AccessCo-inhibition of epidermal growth factor receptor
and insulin-like growth factor receptor 1 enhances
radiosensitivity in human breast cancer cells
Ping Li1, Marlon R Veldwijk2, Qing Zhang1, Zhao-bin Li1, Wen-cai Xu1 and Shen Fu1*Abstract
Background: Over-expression of epidermal growth factor receptor (EGFR) or insulin-like growth factor-1 receptor
(IGF-1R) have been shown to closely correlate with radioresistance of breast cancer cells. This study aimed to
investigate the impact of co-inhibition of EGFR and IGF-1R on the radiosensitivity of two breast cancer cells with
different profiles of EGFR and IGF-1R expression.
Methods: The MCF-7 (EGFR +/−, IGF-1R +++) and MDA-MB-468 (EGFR +++, IGF-1R +++) breast cancer cell lines
were used. Radiosensitizing effects were determined by colony formation assay. Apoptosis and cell cycle
distribution were measured by flow cytometry. Phospho-Akt and phospho-Erk1/2 were quantified by western blot.
In vivo studies were conducted using MDA-MB-468 cells xenografted in nu/nu mice.
Results: In MDA-MB-468 cells, the inhibition of IGF-1R upregulated the p-EGFR expression. Either EGFR (AG1478)
or IGF-1R inhibitor (AG1024) radiosensitized MDA-MB-468 cells. In MCF-7 cells, radiosensitivity was enhanced by
AG1024, but not by AG1478. Synergistical radiosensitizing effect was observed by co-inhibition of EGFR and IGF-1R
only in MDA-MB-468 cells with a DMF10% of 1.90. The co-inhibition plus irradiation significantly induced more
apoptosis and arrested the cells at G0/G1 phase in MDA-MB-468 cells. Only co-inhibition of EGFR and IGF-1R
synergistically diminished the expression of p-Akt and p-Erk1/2 in MDA-MB-468 cells. In vivo studies further verified
the radiosensitizing effects by co-inhibition of both pathways in a MDA-MB-468 xenograft model.
Conclusion: Our data suggested that co-inhibition of EGFR and IGF-1R synergistically radiosensitized breast cancer
cells with both EGFR and IGF-1R high expression. The approach may have an important therapeutic implication in
the treatment of breast cancer patients with high expression of EGFR and IGF-1R.
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Currently, breast cancer is the most common malig-
nancy among women worldwide. Radiotherapy is consi-
dered mandatory for most patients undergoing breast-
conserving surgery and appropriate for women at high
risk of recurrence after mastectomy, but the locoregional
control of breast cancer patients still is disappointed,
especially in some subtypes like basal-like breast cancer
[1]. The patients with basal-like breast cancer are associ-
ated with a high risk of local-regional failure compared* Correspondence: fushen1117@gmail.com
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reproduction in any medium, provided the orto other subtypes [1,2]. One of the features of the pa-
tients is that they have abnormal signaling transduction
pathways like epidermal growth factor receptor (EGFR)
and insulin like growth factor 1 receptor (IGF-1R) [3,4].
These receptor tyrosine kinases have been implicated in
radioresistance of breast cancer in preclinical and clinical
studies [3,5,6], therefore, the combination of targeted
therapy with radiotherapy has been investigated to im-
prove local control rates [5].
Clinical studies of EGFR inhibitors might aid in the
clinical introduction of anti-IGF-1R targeting strategies.
Interactions between IGF-IR and EGFR signaling path-
ways have been previously described [7]. The interactionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation between the two receptors, or indirectly via common
interaction partners such as downstream effectors [7].
Sensitivity to EGFR inhibition has been linked to acquired
mutations in the ATP binding site of the EGFR kinase do-
main and to increased IGF signaling, Co-inhibition of
EGFR and IGF-1R has been found to cause synergy in
growth inhibition and apoptosis induction in human
breast cancer cells [8]. Considering the interplay between
the IGF-1 and EGF systems and their role in the modula-
tion of radiosensitivity, targeting multiple signaling path-
ways may maximize the response to irradiation.
Synergistic radiosensitization has been achieved by co-
inhibition of multi-targets [9]. However, there are no re-
ports about the impacts of co-inhibition of EGFR and
IGR-1R on radiosensitivity of breast cancer cells. In this
study, we aimed to investigate whether co-inhibition of
EGFR and IGF-1R enhances the radiosensitivity of breast
cancer cells with different expression of the two receptors,
and also to assess the potential molecular mechanisms.
Methods
Cell lines and culture
The human breast cancer cell lines MDA-MB-468
(basal-like cell line with high expression of EGFR and
IGF-1R) and MCF-7 (luminal-like cell line with high ex-
pression of IGF-1R, but low expression of EGFR) were
used in this study [10], and purchased from the American
Type Culture Collection (ATCC, Manassas, VA). The
cells were cultured in Eagle’s MEM supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin
(GIBIC).
Reagents
All antibodies were purchased from the Cell Signaling
Technology, Inc (Danvers MA). The selective EGFR
tyrosine kinase inhibitor (AG1478) and the IGF-1R tyro-
sine kinase inhibitor (AG1024) were purchased from
Calbiochem (La Jolla CA). The inhibitors were dissolved
in DMSO to prepare a 10 mM stock solution.
Irradiation
Cells in a monolayer were irradiated at room temperature
using 6MV X-rays from linear accelerators (Siemens,
Germany) with dose rate of 3 Gy/min. A 1.5-cm bolus was
used as a compensator
Cell viability assay
Cells were incubated in the presence of serial increasing
concentrations of AG1478 or AG1024 for 48 h. Then,
20 μM of MTT solution (5 mg/ml) was added into each
well for 4 h. The reaction was stopped by removal of
MTT, and 150 μl DMSO was added into each well, and
then the plates were read at 570 nm. Percentage of cellviability was determined relative to control. Each experi-
ment was done in six replicate wells for each drug con-
centration. All experiments were done in triplicate. The
IC50 values were calculated with the SPSS software
using bliss method.
Colony formation assay
105 Cells were seeded in 60 mm culture dishes, twenty-
four hours later cells were treated with 10 μM AG1478
or/and 10 μM AG1024, control group received DMSO
in the same concentration for 1 hour. Then cells were ir-
radiated with single dose at 0 to 10 Gy with 6MV x rays.
At 48 hours post-irradiation, the cells were detached
from dishes with trypsin, and were seeded at various di-
lutions into 60 mm dishes in normal medium. The cells
were cultured for 14 days. Each result was the average of
at least three independent experiments. Colonies (>50
cells/colony) were fixed and stained with crystal violet.
Survival curves were fitted by the linear-quadratic model
using the Graphpad prism soft (version 5.0). Dose-
modifying factor at 10% survival cells (DMF10%) were
determined by taking the ratio of the radiation doses
at the 10% survival level.
Apoptosis and cell cycle assay by flow cytometry
Cells were treated with inhibitors (10 μM) for 1 h and
were irradiated with 4Gy. They were harvested and
washed with PBS at 48 hours after treatment. They were
stained with propidium iodide (PI) and Annexin V
(KeyGEN, Inc. Nanjing, China) for 10-20 min, and were
detected by flow cytometry (Beckman Coulter, Inc.). For
the analyses of cell cycle, the treated cells were fixed in
70% ethanol and stored at −20°C overnight; the cells
were labeled with propidium iodide (50 μg/ml) and
RNase (100 μg/ml) for 30 min before the analyses
by flow cytometry with Multi-cycle system software
package.
Western blot analysis
MDA-MB-468 cells were exposed to 10 μM of AG1478
and/or 10 μM of AG1024 for 1 hour, and then incubated
with the inhibitors after irradiated at 4Gy. After incuba-
tion for 24 hours, the cells were lysed and separated by
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis and transferred to polyvinylidene fluoride mem-
brane, the membrane were incubated overnight with
primary antibodies at 4°C with gentle shaking, and then
were incubated for 2 h with horseradish peroxidase–
labeled secondary antibody. All membranes were de-
tected using the ECL plus chemifluorescent reagent
(Amersham Biosciences). The extent of protein expres-
sion were quantified by the ImageJ soft from NIH [11]
and normalized by the value of control expression in
each group.
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Female athymic nu/nu mice (4 to 6 weeks old) were obtained
from laboratory animal center of Shanghai institutes for bio-
logical sciences, Chinese Academy of Sciences (Permit Num-
ber: SCXK 2007–005). All animal studies were strictly in
accordance with a protocol approved by Ethic Committee
for Animal Experimentation of Shanghai Jiaotong University.
5 × 106 MDA-MB-468 cells were injected into the flanks of
female athymic nu/nu mice. The mice with tumor volume
100 mm3 were randomly divided into five groups (5 mice/
group), and treated with variable strategies. AG1478 were in-
traperitoneally injected with 10 mg/kg three times per week
for 2 weeks and AG1024 were intraperitoneally injected with
1.5 mg/kg once per day for 2 weeks. Mice were irradiated
30 min after injection of inhibitors with 8 Gy on the first
day. Tumor volume for xenografts was determined by a cali-
per and was calculated as volume = length ×width2/2, where
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Figure 1 Specific inhibition of EGFR by AG1478 or IGF-1R by AG1024
from MDA-MB-468 and MCF-7 cells were analyzed for EGFR (a) and IGF-1R
MDA-MB-468 and MCF-7 cells were treated with the indicated concentratio
or AG1024 (d) for 48 h. (e-f) MDA-MB-468 cells were treated with 10 μM A
MDA-MB-468 cell lysates using antibodies specific for IGF-1R, p-IGF-1R (e) aStatistical analysis
Each experiments were performed in triplicate. For com-
parison of the difference between two groups, Student’s t
test was used. For comparison of the difference between
more than two groups, One-way ANOVA, Bonferroni
were employed for statistical analysis using SPSS 11.0
for windows software. p values <0.05 were considered as
statistically significant.
Results
The impact of inhibition of EGFR or IGF-1R on the cell
viability
MDA-MB-468 and MCF-7 cells have similar expression of
IGF-1R, but EGFR was more expressed in MDA-MB-468
cells compared with MCF-7 cells (Figure 1a-b). Compared
with MCF-7 cells, MDA-MB-468 were more sensitive to
EGFR inhibitor AG1478 (IC50 to MDA-MB-468 and
MCF-7 cells were 40.92 μM and 159.24 μM, respectively)
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. (a-b) Under basal growth conditions, whole-cell extracts obtained
(b) expressions. (c-d) Cellular viability was measured by MTT assay.
ns of AG1478 (c) (Students’ t-test, p = 0.022 at concentration of 50 μM)
G1478 or 10 μM AG1024 for 24 h. Western blot analysis was done on
nd EGFR, p-EGFR (f). * p < 0.05, MDA-MB-468 cells vs. MCF-7 cells.
Li et al. BMC Cancer 2013, 13:297 Page 4 of 9
http://www.biomedcentral.com/1471-2407/13/297to be more sensitive to IGF-1R inhibitor AG1024 as com-
pared to MDA-MB-468 cells (IC50 to MDA-MB-468 and
MCF-7 cells were 58.75 μM and 24.91 μM, respect-
ively) (Figure 1d), Interestingly, AG1024 that downre-
gulated the expression of p-IGF-1R in MDA-MB-468
cells (Figure 1e), resulted into the upregulation of
p-EGFR without influencing the levels of total EGFR
(Figure 1f ).
Co-inhibition of EGFR and IGF-1R synergistically enhanced
the radiosensitizing effect in MDA-MB-468 cells but not in
MCF-7 cells
As shown in Figure 2, AG1478 moderately enhanced the




































































Figure 2 Effect of AG1478 or/and AG1024 on radiosensitivity in MDA
with the following inhibitors: DMSO in same concentration (as control), 10
1 h. After irradiation with indicated dose for 48 h, cells were trypsinized, co
bars represent standard deviation. Points, mean values from three indepen
dose of 10Gy). ** p < 0.05. AG1478 + AG1024 + RT group vs. Other treated gdoses, with a DMF10% of 1.20, but not of MCF-7 cells
(DMF10% of 1.08). AG1024 sensitized both MDA-MB-468
and MCF-7 cells to radiation, with a DMF10% of 1.28, 1.34,
respectively. The radiosensitizing effect was further en-
hanced by the co-inhibition of EGFR and IGF-1R, with a
DMF10% of 1.90 in MDA-MB-468 cells, but not in MCF-7
cells (DMF10% of 1.32).
Co-inhibition of EGFR and IGF-1R combined with
irradiation induced more apoptosis in MDA-MB-468 cells
not in MCF-7 cells
As shown in Figure 3, either AG1478 or AG1024 com-
bined with irradiation moderately induced apoptotic




































































-MB-468 and MCF-7 cells. MDA-MB-468 and MCF-7 cells were treated
μM AG1478 (a, b), 10 μM AG1024 (c, d), or their combination (e, f) for
unted, seeded at different dilutions and incubated for 14 days. Vertical
dent experiments. (One-way ANOVA MDA-MB-468, F = 4.568, p = 0.038 at
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Figure 3 Effect of AG1478 or/and AG1024 plus irradiation on apoptosis in MDA-MB-468 and MCF-7 cells. Cells were exposed to DMSO in
same concentration (as control), AG1478 10 μM, AG1024 10 μM or their combination combined with irradiation at dose of 4 Gy. Results are the
mean value of three experiments, columns, mean; bars, S.D. (One-way ANOVAMDA-MB-468 F = 48.194, p < 0.001), ** p < 0.05, AG1478 + AG1024 + RT
group vs. other treated groups. (a-b): Representative picture of the apoptosis on MDA-MB-468 (a) and MCF-7 (b) cells. (c-d) Graphs show the
percentage of apoptosis on MDA-MB-468 (c) and MCF-7 (d) cells. RT = radiotherapy.
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MTT assays, no such induced apoptosis was observed by
AG1478 plus irradiation in MCF-7 cells compared withirradiation alone (p = 0.141). However, AG1024 plus ir-
radiation induced more apoptotic cells in MCF-7 cells
(p = 0.001). While the cells were treated with both
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tosis was seen in MDA-MB-468 cells. However, the
combination of both inhibitors with irradiation in MCF-
7 cells did not result in further increased apoptosis rela-












































































Figure 4 Effect of AG1478 or/and AG1024 plus irradiation on cell cyc
10 μM, AG1024 10 μM and their combination plus irradiation at dose of 4
represent mean values from three independent experiments. Columns, mea
F = 71.498, p < 0.001; One-way ANOVAS, F = 6.897, p = 0.006; One-way ANO
vs. other treated groups. RT = radiotherapy.Co-inhibition of EGFR and IGF-1R combined with irradiation
significantly induced G0/G1 arrest in MDA-MB-468
cells
As shown in Figure 4, a significant increase in G0/G1



















le in MDA-MB-468 cells. MDA-MB-468 cells were exposed to AG1478
Gy for 48 h. Cell distribution in G0/G1 (a), S (b), G2/M (c) phase. Data
n from three repeated experiments; bars, SD. (One-way ANOVAG0/G1
VAG2/M, F = 12.389, p = 0.001) ** p < 0.05, AG1478 + AG1024 + RT group
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observed. But treatment of AG1024 combined with irradi-
ation did not induced an accumulation of cells in the G0/
G1 phase (p = 0.404, RT vs. RT plus AG1024). Unexpect-
edly, combined treatment with AG1478 and AG1024 plus
irradiation resulted in a significant accumulation in the
G0/G1 phase in more than 80% of the cells and a signifi-
cant decrease of S and G2/M phase cells to less than 8%
(p < 0.05, compared with other treated groups).
Enhancement of the radiosensitizing effect of MDA-MB-468
cells through synergistical downregulation of Akt and
Erk1/2
As shown in Figure 5, when MDA-MB-468 cells were
treated with AG1478 or AG1024 plus irradiation for 24 h,
p-Akt level was partially reduced, but p-Akt was fully di-
minished by the combination plus irradiation. On the
other hand, AG1478 or AG1024 plus irradiation had min-
imal influence on p-Erk1/2 expression in MDA-MB-468
cell lines, combining both inhibitors with irradiation could
significantly decreased the expression of p-Erk.
Co-inhibition of EGFR and IGF-1R combined with irradiation
significantly inhibits MDA-MB-468 xenograft growth
As shown in Figure 6, the in vivo studies of co-
inhibition of EGFR and IGF-1R on the anti-tumor effectRT
1.0 0.9 0.6 0
1.0 1.2 0.9 0
Figure 5 Effect of AG1478 or/and AG1024 plus irradiation on total an
cells were exposed to AG1478 (10 μM for 1 hour) and/or AG1024 (10 μM fo
phosphorylated Akt, total and phosphorylated Erk1/2 were examined. The
panel, these represent phosphor-protein relative to total protein, the phosp
control cells, the cells were assigned the value = 1. RT = radiotherapy.of radiotherapy were determined in a nu/nu MDA-MB
-468 xenograft mouse model. The irradiation group had
minimal effects on tumor growth delay compared with
control group. Either AG1478 or AG1024 combined
with irradiation could inhibit the tumor growth com-
pared with irradiation alone (p < 0.001). Compared with
those two treatments, combining AG1478 and AG1024
with irradiation led to the most significant inhibition of
tumor growth (p < 0.001) at day 31 post treatment.
Discussion
EGFR and IGF-1R are commonly overexpressed in a sig-
nificant number of cancers, included breast cancer
[13,14], and its overexpression have been implicated to
influence the response to irradiation in breast cancer
cells [15]. There were about 65% with the overexpression
of EGFR and 22.5% with the overexpression of IGF-1R
in basal-like breast cancer patients [4,6]. The abnormal
expression of those receptors have been observed to be
associated with poor prognosis and unfavorable response
to radiotherapy [6]. Since there were a cross-talk be-
tween EGFR and IGF-1R pathways and the cross-talk
may be one of reasons for the resistance of cancer cells
to drug and radiotherapy [16,17], co-inhibition of both
pathways have been investigated and found out that it
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r 1 hour), and were irradiated at 4Gy for 24 hours. Total and
density of each band were shown under the p-Akt and p- Erk1/2






























Figure 6 In vivo radiosensitization of AG1478 or/and AG1024 in a nu/nu MDA-MB-468 xenograft model. The treatment began when
mean tumor volume reached 100 mm3, mice treated with DMSO, AG1478, AG1024, or a combination. AG1478 were intraperitoneally injected
with 10 mg/kg three times per week for 2 weeks and AG1024 were intraperitoneally injected with 1.5 mg/kg once per day for 2 weeks.
Irradiation with 8 Gy was given 30 min after drugs treatment on the first day. (One-way ANOVA F = 101.86, p < 0.001) ** p < 0.05, AG1478 +
AG1024 + RT group vs. other treated groups. RT = radiotherapy.
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inhibition of EGFR and IGF-1R would further impact
the response of breast cancer cells to irradiation.
In our studies, the different response to irradiation after
co-inhibition of EGFR and IGF-1R in MDA-MB-468 and
MCF-7 cells adds to the evidence that both signaling path-
ways may be involved in the treatment response. Firstly,
the radiosensitizing effect by either EGFR or IGF-1R in-
hibitor depended on the expression level of EGFR and
IGF-1R in both cells. Secondly, inhibition of IGF-1R resul-
ted in a slight upregulation of p-EGFR in MDA-MB-468
cells, which corroborates the study by other reports
[15,18]. Furthermore, both cell lines had a different sensi-
tivity to AG1024 although both cell lines had similar ex-
pression level of IGF-1R (Figure 1b). Those findings
supported that there were the interaction between EGFR
and IGF-1R. Co-inhibition of EGFR and IGF-1R plus ir-
radiation resulted in significantly increased apoptosis and
mitotic death relative to any single inhibitor plus irradi-
ation in MDA-MB-468 cells. In addition, in vivo studies
further verify the radiosensitizing effects by co-inhibition
of EGFR and IGF-1R in MDA-MB-468 xenografts. These
results added the evidence that both EGFR and IGF-1R
may be involved in the regulation of radiosensitivity, the re-
sponse to radiotherapy in breast cancer like basal-like sub-
type may be improved by co-targeting EGFR and IGF-IR.
The possible mechanism for synergistical radiosensi-
tizing effect by co-targeting EGFR and IGF-IR may be
associated with their collective downstream pathways --
PI3K/Akt and Ras/Raf/MAPK, both pathways involved
in the regulation of radiosensitivity through the down-
stream proteins Akt and Erk1/2 [19,20]. It has been
reported that inhibition of PI3K/Akt signaling pathway
led to radiosensitize the tumor cell by affecting repair ofDNA double-strand breaks via DNA-PKcs, and this pathway
inactivates Bad and caspase-9 and activates p21, p27 and
Mre11, which are associated with cellular radiosensitivity
[21,22]. Activated Erk1/2 has also been observed to confer
radioresistance in breast cancer cells [19]. Inhibition of both
Akt and Erk1/2 may achieve synergistic radiosensitization in
some subtypes of cancer cells. In present study, we found
that co-inhibition of EGFR and IGF-1R could completely
abolished the p-Akt and p-Erk1/2 and resulted in a synergis-
tic radiosensitizing effect in MDA-MB-468 cells. These re-
sults suggested that co-targeting EGFR and IGF-1R
radiosensitized the MDA-MB-468 cells through both PI3K/
Akt and MAPK signaling pathways.
In addition to the potential of growth factor inhibitors
to reverse pro-survival signal, they may also sensitize
cells to irradiation by altering cell cycle control. The
growth factor inhibitors have been shown to induce G0/
G1 arrest, and this alteration redistributes cells from
relatively radioresistant S phase to more sensitive phase
like late G1 or G2/M [23]. On the other hand, although
tumor cells arrest at some checkpoints in order to repair
radiation-induced damage, it require growth factors to
proceed effectively [24], therefore, inhibition of growth
factor receptor make the process unable to facilitate re-
pair, contributing to cell death. Our data show that co-
targeting EGFR and IGF-1R plus irradiation significantly
reduced S phase and arrest cells at G0/G1 phase in
MDA-MB-468 cells, profound tumor cell kill was ob-
served, therefore, the cells were sensitized to irradiation.
Conclusion
In summary, both in vitro and in vivo studies support that
synergistic radiosensitizing effect by co-inhibition of both
pathways mainly through the synergistic downregulation
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egy of block more than one pathway holds promise to en-
hance the radiosensitivity of some subtypes breast cancer,
but it is critical to evaluate the profile of expression of
EGFR and IGF-1R in breast cancer patients before the
strategy is applied into the clinical setting.
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